Procter & Gamble's recent announcement of worldwide price increases for up to 70% of its portfolio in response to commodity cost increases likely foreshadowed commentary other US consumer health product manufacturers will offer with their quarterly results.
Similar comments likely are coming in major firms’ October-December results in the consumer health sector starting with Johnson & Johnson’s 2021 full-year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?